香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司關於獲得藥物臨床試驗批准通知書的公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 劉寧 中國，珠海 二零二五年六月二十四日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 1 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-048 丽珠医药集团股份 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-048 丽珠医药集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 剂型：注射剂 申请事项：临床试验申请 注册分类：化学药品 1 类 申请人：丽珠医药集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 4 月 14 日受理的 YJH-012 注射液临床试验申请符合药品注册的有关要求，同 意本品开展痛风适应症临床试验。 二、药品研发及相关情况 近日，丽珠医药集团股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的《药物临床试验批准通知书》（通知书编号：2025LP01629）， 批准 YJH-012 注射液开展临床试验。现将有关详情公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：YJH-012 注射液 三、药品的市场情况 根据CDE审评中心网站显示，截至目前，国内无同适应症小核酸产品上市。 四、风险提示 由于药物研发的特殊性，从临床试验到投产上市的周期长、环节多 ...

Core Viewpoint - The company announced that its subsidiary, Lizhu Group, received approval from the National Medical Products Administration for clinical trials of YJH-12 injection, a new siRNA drug for gout [1] Group 1: Company Developments - Lizhu Group, a subsidiary of the company, is collaborating with Youjia (Hangzhou) Biopharmaceutical Technology Co., Ltd. to develop the YJH-12 injection [1] - The total research and development expenses incurred for YJH-12 injection amount to approximately RMB 25.7386 million [1] - There are currently no similar small nucleic acid products approved for the same indication in the domestic market [1]

Investment Rating - The report suggests a positive outlook for the epilepsy drug industry, highlighting potential breakthroughs in new drug targets and a rich pipeline of anti-seizure medications (ASMs) under development [3][59]. Core Insights - Epilepsy is a common neurological disorder with a significant patient population, estimated at 51.7 million globally and approximately 9 million in China, with 500,000 to 600,000 active cases annually [3][59]. - The mechanisms of epilepsy are complex, leading to a substantial treatment gap, as about 30% of patients do not achieve effective seizure control with current therapies [3][59]. - The research and development pipeline for ASMs is active, focusing on precision medicine and multi-target mechanisms, with promising candidates like XEN1101, Bexicaserin, and Zorevunersen showing advanced clinical progress [3][59]. Summary by Sections Section 1: Epilepsy as a Common Neurological Disorder - Epilepsy affects a large number of individuals, with a global prevalence rate of 658 per 100,000 people and a 10.8% increase in prevalence from 1990 to 2021 [8]. - In China, the estimated prevalence is about 7.0 per 1,000, with 40,000 new cases each year, making it the second most common neurological condition after headaches [8][29]. Section 2: ASMs as the Current Treatment of Choice - ASMs are the primary treatment for epilepsy, but they have limited efficacy and significant side effects, which continue to impact patient outcomes [20][29]. - The market for epilepsy treatment is projected to grow from approximately $8.6 billion in 2024 to $13.9 billion by 2034, with a CAGR of 5.1% [24][29]. Section 3: Active R&D Pipeline for ASMs - The focus of ASM development is on precision treatment and individualized medication, with over 200 projects currently disclosed, many in advanced clinical stages [33][36]. - Notable candidates include XEN1101, a potassium channel opener, which has shown promising results in reducing seizure frequency in clinical trials [39][44]. Section 4: Valuation of Key Companies - The report includes a valuation table for key companies in the epilepsy drug market, highlighting their market capitalization and projected revenues [61]. - Companies such as Hainan Haiyao and Lizhu Group are noted for their active pipelines and potential for growth in the epilepsy treatment sector [61].

Core Viewpoint - The article highlights the ongoing issues with the timely supply of drugs and medical devices following centralized procurement in various regions of China, indicating a significant number of products have not established delivery relationships post-selection, which raises concerns about the reliability of selected suppliers [1][9]. Group 1: Issues with Drug Supply - As of May 31, 2023, 443 drug specifications have not established timely delivery relationships after centralized procurement in Guangzhou, with nearly 70% of the 221 identified underperforming products having a delivery rate of 0 [9][10]. - The Hebei Provincial Medical Procurement Center has announced that certain companies will be rated as "generally" untrustworthy due to inadequate delivery services, including Suzhou Terui Pharmaceutical and Lizu Group, which are involved in multiple national procurement batches [2][5]. Group 2: Specific Products and Companies - Lizu Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, a significant drop from its previous market price of 700-800 yuan, reflecting a price reduction of over 90% [2]. - Northland Pharmaceutical's iohexol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [3]. Group 3: Regulatory Framework and Consequences - The Hebei Provincial Medical Procurement Center has established a credit evaluation system for pharmaceutical pricing and procurement, categorizing untrustworthy behavior into four levels: "general," "medium," "serious," and "particularly serious" [7]. - Companies identified as untrustworthy may face consequences such as written warnings, risk notifications on procurement platforms, and restrictions on the procurement qualifications of related drugs and materials [7]. Group 4: Broader Supply Issues - Beyond medical institutions, there are also reported supply shortages in designated pharmacies, with 422 drugs not supplied, affecting various products and involving 289 manufacturers [8].

Core Viewpoint - The announcement from the Hebei Provincial Medical Supplies Procurement Center indicates that several companies are being rated as "generally" untrustworthy due to inadequate delivery services for selected products in the national centralized procurement process [1][2][3] Group 1: Companies Involved - Companies listed for potential untrustworthiness include Suzhou Terui Pharmaceutical, Sihuan Pharmaceutical, Lijun Group, Jiangxi Yongfeng Kande Pharmaceutical, Guangdong Saifeng Pharmaceutical, Beijing Fule Technology, and Beijing Beilu Pharmaceutical [1][2] - Lijun Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, down from a previous market price of 700-800 yuan, representing a price drop of over 90% [1] - Beilu Pharmaceutical's iopamidol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [1] Group 2: Regulatory Framework - The Hebei Provincial Medical Security Bureau established a credit evaluation system for drug pricing and procurement in late 2020, categorizing untrustworthy behavior into four levels: "general," "moderate," "serious," and "particularly serious" [3] - The "general" untrustworthiness rating applies to companies that fail to fulfill procurement or delivery contracts without valid reasons and do not notify procurement agencies in advance, provided it does not severely impact clinical treatment [3] - Once a company is rated as untrustworthy, the provincial procurement center will implement measures such as written warnings, risk notifications on procurement platforms, and restrictions on procurement qualifications [3] Group 3: Broader Industry Context - The issue of supply shortages is not limited to medical institutions; designated pharmacies in Hebei also face significant shortages, with 422 drugs reported as unavailable [4] - Other regions, including Liaoning, Hainan, and Guangzhou, have also reported issues with selected companies failing to deliver drugs on time since the implementation of centralized procurement policies [4] - As of May 31, 2023, 443 drug varieties had not established timely delivery relationships post-procurement, with nearly 70% of the identified varieties having a delivery rate of 0% [4] Group 4: Future Developments - By the end of 2024, 612 companies were rated as generally untrustworthy, 76 as moderately untrustworthy, 40 as seriously untrustworthy, and 7 as particularly seriously untrustworthy [5] - A new standard for credit evaluation will be implemented starting from the third quarter of 2025, simplifying the rating system from four levels to three: "untrustworthy," "seriously untrustworthy," and "particularly seriously untrustworthy" [6]

Group 1 - Over 1500 companies have completed their dividend distribution for the year 2024, with 1532 companies having implemented their dividend plans as of June 9 [2][3] - Companies such as Haibo Sichuang, Lizhu Group, Huate Dain, and Midea Group are among those with the highest proposed dividend amounts per share [2][3] - Midea Group plans to distribute 35 yuan in cash for every 10 shares, with the record date on June 11, 2025, and the payment date on June 12, 2025 [2][3] Group 2 - Renhe Pharmaceutical announced a cash dividend of 1.5 yuan per 10 shares, with the record date on June 16, 2025, and the payment date on June 17, 2025 [3] - Haibo Sichuang plans to distribute a cash dividend of 1.1 yuan per share, with the record date on June 12, 2025, and the payment date on June 13, 2025 [4] Group 3 - Several companies are announcing mid-term dividend plans, with Zhangjiang Hi-Tech proposing to increase mid-term cash dividends based on profitability and cash flow [5][6] - High New Development is seeking authorization to establish a mid-term dividend plan for 2025, emphasizing the need for positive earnings and cash flow [6] Group 4 - The Shanghai Stock Exchange held a meeting to discuss enhancing high dividend and high yield company valuations, indicating a push for increased dividend distributions [7] - Experts suggest that dividends can boost investor confidence and reflect a company's cash strength and profitability [7]

Group 1 - The stock price of Lijun Group (000513) closed at 36.49 yuan on June 6, 2025, up 0.25% from the previous week [1] - The company's total market capitalization is 32.991 billion yuan, ranking 14th out of 150 in the chemical pharmaceutical sector and 423rd out of 5148 in the A-share market [1] - The highest intraday price reached 37.99 yuan on June 5, 2025, while the lowest was 36.28 yuan on June 3, 2025 [1] Group 2 - Lijun Group plans to repurchase A-shares and H-shares, with 11,318,855 A-shares repurchased, accounting for 1.25% of the total share capital, and a total expenditure of approximately 406.84 million yuan [1][3] - The company has also repurchased and canceled 7,245,300 H-shares, with no new H-share repurchase planned [1][3] - The 2024 annual equity distribution plan for A-shares includes a cash dividend of 11.00 yuan per 10 shares, totaling approximately 652.27 million yuan [1][3]

海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司 2024 年年度權益分派（A 股）實施公告》，僅供參閱。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 中國，珠海 二零二五年六月六日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 劉寧 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-047 丽珠医药集团股份 ...

Core Viewpoint - The company has announced a cash dividend distribution plan for its A-share shareholders, with a total cash dividend amounting to RMB 652,271,903.80 (including tax), translating to a cash dividend of RMB 11.00 per 10 shares for the fiscal year 2024 [1][2]. Group 1: Dividend Distribution Details - The cash dividend distribution is based on the total A-share capital of 604,293,313 shares, excluding repurchased but not canceled shares [1]. - The cash dividend per share after the distribution will be RMB 1.0793961, which will be deducted from the closing price on the ex-dividend date [2]. - The dividend distribution plan was approved at the company's annual general meeting held on May 29, 2025 [2]. Group 2: Shareholder Eligibility and Taxation - The eligible A-share shareholders for the dividend are those registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of June 12, 2025 [3]. - For Hong Kong market investors and foreign institutions, the cash dividend will be RMB 9.90 per 10 shares after tax deductions [2]. - The company will not withhold individual income tax for certain shareholders, with tax obligations calculated based on the holding period upon stock transfer [3]. Group 3: Important Dates - The record date for the dividend distribution is set for June 12, 2025, and the ex-dividend date is June 13, 2025 [3].